Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer - GeparQuinto

Trial Profile

A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer - GeparQuinto

Completed
Phase of Trial: Phase III

Latest Information Update: 23 May 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Everolimus (Primary) ; Lapatinib (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Paclitaxel; Trastuzumab
  • Indications Early breast cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms GeparQuinto
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 23 May 2018 Results (n=2600) assessing the effects of BRCA1/2 mutations on pathologic complete response (pCR) and disease-free survival (DFS) in a cohort of patients with TNBC treated with anthracycline and taxane-containing chemotherapy, with or without bevacizumab, were published in the Journal of Clinical Oncology.
    • 15 Mar 2018 Primary endpoint (To compare the pCR rates of neoadjuvant treatment in Setting III) has not been met as per the results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top